Glax­o­SmithK­line drops out of Ebo­la vac­cine de­vel­op­ment as R&D shifts re­sources to fran­chise drugs

GSK’s R&D or­ga­ni­za­tion has a new set of pri­or­i­ties — which doesn’t in­clude Ebo­la vac­cines.

The phar­ma gi­ant has hand­ed over ex­per­i­men­tal vac­cines for two va­ri­eties …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER